A randomized phase 2 study combining midostaurin, low-dose cytarabine and venetoclax in newly diagnosed AML ≥60 years

In randomized studies, addition of FLT3 inhibitors failed to improve survival in older patients with FLT3-ITD AML unfit for intensive chemotherapy. Although hypomethylating agents or low-dose cytarabine combined with venetoclax is standard, FLT3-ITD is an important mechanism of resistance and a barrier to improved survival. Recent studies show promise for the addition of gilteritinib or quizartinib to less intensive venetoclax-based therapy, however resulting marrow toxicity requires substantial reductions to administered treatment. The INTERVENE study (Investigating Novel Triplets to Extend Remission with VENetoclax in Elderly AML) (ACTRN12619001655134) examined the role of midostaurin (M) administered sequentially after low-dose cytarabine (L) combined with venetoclax (V) in patients with newly diagnosed AML ≥60 years with non-adverse karyotype. After a run-in phase (n=18) established that LDAC combined with venetoclax from days 1-28 and midostaurin from days 11-28 was tolerable, 120 patients were randomized 2:1 to receive either LVM or LV. For the primary endpoint, LVM did not improve composite complete remission (CRc), compared to LV (72% vs 68%). Combining midostaurin with LV enhanced CRc among the sub-group of patients (n=29) with FLT3-ITD (82% vs 57%, difference = 25%, 0.85 posterior probability true difference > 5%, 95% CrI: -10 to 59%) and improved FLT3-ITD clearance as measured by ultrasensitive NGS (65% vs 0%), resulting in longer OS (median 24.2 vs 8.8 months, HR=0.34, 95% CrI: 0.071 to 0.960), compared to LV. In conclusion, midostaurin combined with low-dose cytarabine and venetoclax is well-tolerated and may have a role in newly diagnosed FLT3-ITD AML unfit for intensive chemotherapy.

Authors

Institutions

Publication Details

Journal
Blood
Published
2026-10-19
DOI
https://doi.org/10.1182/blood.2026035389
Primary Topic
Acute Myeloid Leukemia Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A randomized phase 2 study combining midostaurin, low-dose cytarabine and venetoclax in newly diagnosed AML ≥60 years

Andrew H. Wei, Shaun A. Fleming, Anoop Kumar Enjeti, Ashish R. Bajel et al.
Blood
Acute Myeloid Leukemia Research
article

A randomized phase 2 study combining midostaurin, low-dose cytarabine and venetoclax in newly diagnosed AML ≥60 years

Andrew H. Wei, Shaun A. Fleming, Anoop Kumar Enjeti, Ashish R. Bajel, Julian P. Cooney, Hannah L. Rose, Rachel M. Koldej, Chong Chyn Chua, Carolyn S. Grove, Jad Othman, Stephen B. Ting, John Reynolds, Devendra Hiwase, Natasha S. Anstee, Derek McCulloch, Paula V. Marlton, David Ritchie, Kate Mason, Travis Perera, ShuhYing Tan, Peter Browett, Edward S. Morris, Amanda Johnston, Chun-kei-kris Kris Ma, Wei-Hsun Hsun Hsu
article en

Abstract

In randomized studies, addition of FLT3 inhibitors failed to improve survival in older patients with FLT3-ITD AML unfit for intensive chemotherapy. Although hypomethylating agents or low-dose cytarabine combined with venetoclax is standard, FLT3-ITD is an important mechanism of resistance and a barrier to improved survival. Recent studies show promise for the addition of gilteritinib or quizartinib to less intensive venetoclax-based therapy, however resulting marrow toxicity requires substantial reductions to administered treatment. The INTERVENE study (Investigating Novel Triplets to Extend Remission with VENetoclax in Elderly AML) (ACTRN12619001655134) examined the role of midostaurin (M) administered sequentially after low-dose cytarabine (L) combined with venetoclax (V) in patients with newly diagnosed AML ≥60 years with non-adverse karyotype. After a run-in phase (n=18) established that LDAC combined with venetoclax from days 1-28 and midostaurin from days 11-28 was tolerable, 120 patients were randomized 2:1 to receive either LVM or LV. For the primary endpoint, LVM did not improve composite complete remission (CRc), compared to LV (72% vs 68%). Combining midostaurin with LV enhanced CRc among the sub-group of patients (n=29) with FLT3-ITD (82% vs 57%, difference = 25%, 0.85 posterior probability true difference > 5%, 95% CrI: -10 to 59%) and improved FLT3-ITD clearance as measured by ultrasensitive NGS (65% vs 0%), resulting in longer OS (median 24.2 vs 8.8 months, HR=0.34, 95% CrI: 0.071 to 0.960), compared to LV. In conclusion, midostaurin combined with low-dose cytarabine and venetoclax is well-tolerated and may have a role in newly diagnosed FLT3-ITD AML unfit for intensive chemotherapy.

Blood
Royal Adelaide Hospital (AU), The Royal Melbourne Hospital (AU), University of Auckland (NZ), Walter and Eliza Hall Institute of Medical Research (AU), Geelong Hospital (AU), Royal Prince Alfred Hospital (AU), Royal North Shore Hospital (AU), Peter MacCallum Cancer Centre (AU), Townsville Hospital (AU), Fiona Stanley Hospital (AU), Wellington Hospital (NZ), Princess Alexandra Hospital (AU), The Alfred Hospital (AU), Sir Charles Gairdner Hospital (AU), Christchurch Hospital (NZ), Westmead Hospital (AU), St Vincent's Hospital Melbourne (AU), Eastern Health (AU), Monash Health (AU), Australasian Leukaemia and Lymphoma Group (AU), Alfred Health (AU), Central Adelaide Local Health Network, NSW Health Pathology (AU), Monash University (AU), University of Newcastle Australia (AU)
Openalex Percentile: Top 12%
Acute Myeloid Leukemia Research
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.